Drawn from posts in the Medicine category, newest first. Each answer reads as a citable claim and links back to the source post for the trial data, the regulatory context, or the strategic argument.
The angle: medicine as a competitive industry shaped by patents, trial endpoints, and clinical translation, not as a public-relations narrative. The flagship coverage is the GLP-1 race between Novo Nordisk and Eli Lilly, where the entire $20B Ozempic franchise has to be replaced before the 2031 patent cliff.
Recurring questions: why oral semaglutide destroys 99% of its active ingredient before reaching the bloodstream, why Foundayo skips that problem entirely, why Novo lost 75% from June 2024 after CagriSema underperformed Zepbound head-to-head, what Amycretin’s 24.3% Phase 1 weight loss signals for the post-patent product map, how Isomorphic Labs’ IsoDDE benchmark scores against AlphaFold 3 on protein-ligand prediction.
The default move on this beat: find the constraint that closes off the easy story, then describe what’s actually happening inside it. Answers lead with the trial endpoint or the bioavailability number, not the press release.
Per the EMA assessment report, only 0.4 to 1% of oral semaglutide reaches the bloodstream. The permeation enhancer SNAC (salcaprozate sodium) buffers stomach acid and fluidizes gastric cell membranes, allowing a small fraction of the peptide to cross. The oral 25mg daily dose accordingly uses substantially more active ingredient than the equivalent weekly injection.
From: Why Lilly's Weight Loss Pill Isn't a Peptide
Combined Novo Nordisk and Eli Lilly GLP-1 revenue reached approximately $70 billion in 2025. Per the companies' Q4 2025 disclosures, Lilly's tirzepatide franchise (Mounjaro + Zepbound) generated $36.5 billion and Novo's semaglutide franchise generated roughly $33 billion. Lilly's US market share was reported at 57% as of mid-2025.
From: Why Lilly's Weight Loss Pill Isn't a Peptide
Early data favors expansion over cannibalisation. The statin precedent is instructive: after generic atorvastatin launched in 2011, total statin use expanded from 31 million to 92 million Americans by 2019, a 197% increase. Current GLP-1 penetration is under 5% of eligible US adults versus 35%+ for statins, leaving meaningful room as oral delivery reduces friction.
From: Why Lilly's Weight Loss Pill Isn't a Peptide
Semaglutide's core US patent expires December 5, 2031, with formulation patents extending to 2033. International patents in Canada, China, India, and Brazil are expiring in 2026, opening the door to generic and biosimilar competition outside the US. Tirzepatide patents extend into the mid-2030s.
From: Why Lilly's Weight Loss Pill Isn't a Peptide
Two oral GLP-1 pills are FDA approved for weight loss: Novo Nordisk's oral Wegovy pill (semaglutide 25mg), approved December 2025 and launched January 2026, and Eli Lilly's Foundayo (orforglipron), approved April 1, 2026. Behind them, Novo's oral amycretin enters Phase 3 in 2026, Structure Therapeutics' aleniglipron targets mid-2026 Phase 3 start, and Viking Therapeutics' VK2735 oral showed Phase 2 data with elevated discontinuation rates at the highest dose.
From: Why Lilly's Weight Loss Pill Isn't a Peptide
Per Lilly's disclosure, Foundayo starts at $149 per month for the lowest dose for self-pay patients. Eligible commercially insured patients may pay as little as $25 per month with the savings card. Eligible Medicare Part D individuals may be able to get Foundayo for $50 per month beginning July 2026. The oral Wegovy pill is priced at $149 to $299 per month depending on dose.
From: Why Lilly's Weight Loss Pill Isn't a Peptide
IsoDDE (Isomorphic Drug Design Engine) is a unified computational drug design system Isomorphic Labs released on February 10, 2026. It runs protein structure prediction, ligand binding, affinity estimation, and pocket identification in concert. Per Isomorphic's own reported benchmarks, on the hardest protein-ligand prediction tasks IsoDDE achieves approximately a 50% success rate versus roughly 23% for AlphaFold 3, with reported antibody-antigen modelling gains relative to AlphaFold 3 and Boltz-2 and a reported Pearson correlation of 0.85 on binding affinity prediction. These are the company's published numbers; readers should consult the underlying paper for full methodology.
From: AI Can Now Design Drugs in Seconds; We Still Can't Tell You If They Work.
No. As of February 2026, no AI-discovered drug has received FDA approval. The most advanced AI-discovered candidate publicly reported is Insilico Medicine's rentosertib (ISM001-055), which reached Phase IIa with positive results published in Nature Medicine in June 2025. Isomorphic Labs has publicly targeted late 2026 for its first clinical candidates.
From: AI Can Now Design Drugs in Seconds; We Still Can't Tell You If They Work.
Per published industry data, AI-discovered molecules have shown 80-90% Phase I success rates, above the historical 40-65% average, which the data interprets as consistent with AI being able to design safe, tolerable molecules. Phase II success rates remain roughly 40%, broadly comparable to traditionally discovered drugs. The data suggests AI has not yet demonstrated improvement in predicting clinical efficacy, only safety and pharmacokinetic properties. If both trends hold, end-to-end success rates could roughly double from the historical 5-10% to 9-18%.
From: AI Can Now Design Drugs in Seconds; We Still Can't Tell You If They Work.
Per public deal disclosures, Isomorphic has partnerships with Eli Lilly ($45M upfront, up to $1.7B in milestones), Novartis ($37.5M upfront, $1.2B+ in milestones, expanded February 2025), and Johnson & Johnson (terms undisclosed, announced January 2026). Total disclosed value exceeds $4 billion in milestone-pay potential; the ratio between milestone-contingent and upfront cash is consistent with the industry's typical caution about earlier-stage drug discovery deals.
From: AI Can Now Design Drugs in Seconds; We Still Can't Tell You If They Work.
Isomorphic has reported strong computational benchmark numbers but trails on clinical-stage progress per public disclosures. Insilico Medicine has 10+ IND approvals across 31 programs and the most advanced AI-discovered clinical candidate (rentosertib, Phase IIa). Recursion, which absorbed Exscientia in a $688M merger, takes a phenomics-first approach with 65 petabytes of biological imaging data. Both Insilico and Recursion own wet-lab infrastructure that Isomorphic does not, per public statements. Isomorphic's structural advantages are Alphabet-scale compute, the AlphaFold lineage, and its unified architecture.
From: AI Can Now Design Drugs in Seconds; We Still Can't Tell You If They Work.
Isomorphic sits within Alphabet's Other Bets segment, which posted a $3.6 billion operating loss in 2025 against Alphabet's $132 billion net income. Isomorphic raised a $600 million external round led by Thrive Capital in March 2025. Alphabet can sustain this investment indefinitely, which is itself a competitive advantage over cash-constrained biotech startups.
From: AI Can Now Design Drugs in Seconds; We Still Can't Tell You If They Work.
Isomorphic Labs CEO Demis Hassabis said at Davos 2026 that the company expects its first AI-designed drugs to enter clinical trials by the end of 2026, pushing back an earlier target of 2025. The company hired Dr. Ben Wolf as CMO in June 2025 and opened a Cambridge, Massachusetts office, signaling clinical-stage staffing.
From: AI Can Now Design Drugs in Seconds; We Still Can't Tell You If They Work.
Per Novo Nordisk's February 23, 2026 announcement, CagriSema did not meet the primary endpoint of non-inferiority to Eli Lilly's tirzepatide (Zepbound). CagriSema reported 23.0% weight loss at 84 weeks versus 25.5% for tirzepatide on the on-treatment estimand, and 20.2% versus 23.6% on intention-to-treat.
From: Novo Was Europe's Most Valuable Company
The decline compounded across multiple events: a July 2025 guidance cut on US pricing headwinds, 9,000 job cuts announced in September 2025, a February 2026 guidance for the first revenue decline in modern history (adjusted sales down 5-13%), and the CagriSema REDEFINE 4 announcement on February 23, 2026. Structural pricing pressure from MFN, IRA negotiations, and international patent expiries are the underlying drivers cited in the company's disclosures.
From: Novo Was Europe's Most Valuable Company
After the CagriSema selloff, Novo trades at roughly 11x forward earnings and roughly 8x EV/EBITDA, lower than Merck (14x), AstraZeneca (20x), and AbbVie (17x). This is a notable compression from the 2024 peak multiple.
From: Novo Was Europe's Most Valuable Company
The FDA decision on Eli Lilly's orforglipron is expected April-May 2026. Orforglipron is an oral non-peptide GLP-1 with no food restrictions or fasting requirements. Goldman Sachs has projected orforglipron capturing 60% oral GLP-1 market share by 2030.
From: Novo Was Europe's Most Valuable Company
Likely yes, based on the REDEFINE 1 and 2 placebo-controlled data submitted in December 2025, with a decision expected late 2026. The commercial implications of approving a drug behind the market leader on a head-to-head comparison are a separate question from the regulatory pathway.
From: Novo Was Europe's Most Valuable Company